LYEL vs. ADCT, ERAS, VERV, ALLO, ALEC, SUPN, TARO, AVDL, KURA, and MNKD
Should you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include ADC Therapeutics (ADCT), Erasca (ERAS), Verve Therapeutics (VERV), Allogene Therapeutics (ALLO), Alector (ALEC), Supernus Pharmaceuticals (SUPN), Taro Pharmaceutical Industries (TARO), Avadel Pharmaceuticals (AVDL), Kura Oncology (KURA), and MannKind (MNKD). These companies are all part of the "medical" sector.
ADC Therapeutics (NYSE:ADCT) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, community ranking, risk and valuation.
ADC Therapeutics received 38 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 65.00% of users gave ADC Therapeutics an outperform vote while only 56.00% of users gave Lyell Immunopharma an outperform vote.
Lyell Immunopharma has lower revenue, but higher earnings than ADC Therapeutics. Lyell Immunopharma is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.
ADC Therapeutics has a net margin of -330.17% compared to ADC Therapeutics' net margin of -335,794.09%. Lyell Immunopharma's return on equity of 0.00% beat ADC Therapeutics' return on equity.
ADC Therapeutics has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.52, suggesting that its share price is 152% less volatile than the S&P 500.
In the previous week, ADC Therapeutics and ADC Therapeutics both had 1 articles in the media. ADC Therapeutics' average media sentiment score of 0.94 beat Lyell Immunopharma's score of 0.01 indicating that Lyell Immunopharma is being referred to more favorably in the news media.
ADC Therapeutics presently has a consensus target price of $9.00, indicating a potential upside of 147.59%. Lyell Immunopharma has a consensus target price of $4.00, indicating a potential upside of 143.90%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, equities analysts clearly believe ADC Therapeutics is more favorable than Lyell Immunopharma.
41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 4.1% of ADC Therapeutics shares are held by company insiders. Comparatively, 25.1% of Lyell Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
ADC Therapeutics beats Lyell Immunopharma on 10 of the 17 factors compared between the two stocks.
Get Lyell Immunopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyell Immunopharma Competitors List
Related Companies and Tools
